Jane Hughes
Chief Tech/Sci/R&D Officer presso GYROSCOPE THERAPEUTICS HOLDINGS PLC
Profilo
Jane Hughes holds the position of Chief Scientific Officer at Gyroscope Therapeutics Holdings Plc.
In the past she held the position of Director-Discovery Medicine & Immuno Inflammation at GlaxoSmithKline Plc and Senior Director-Integrated Drug Discovery at Charles River Laboratories, Inc.
She received a doctorate from Keele University.
Posizioni attive di Jane Hughes
Società | Posizione | Inizio |
---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Precedenti posizioni note di Jane Hughes
Società | Posizione | Fine |
---|---|---|
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Corporate Officer/Principal | 01/11/2018 |
GSK PLC | Corporate Officer/Principal | 01/06/2017 |
Formazione di Jane Hughes
Keele University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GSK PLC | Health Technology |
Aziende private | 2 |
---|---|
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Commercial Services |
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |